Synthetic Study of 2-((6,7,8,9-Tetrahydro-5H-cyclohepta(b)pyridin-9-yl)-sulfinyl)-1H-benzimidazole Analogs and Their Biological Properties as Novel Proton Pump Inhibitors.

Yamada, Shin‐ichi; Goto, T.; Yamaguchi, Taichi; Aihiara, Kazuyuki; Kogi, Kentaro; Narita, Sen-ichi

doi:10.1248/cpb.43.421

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

2014

Publication Types

Select...

Article4

Other1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The successful results of our study prompted us to extend the substrate scope of this method to a series of cyclic ketones 4. Thus, nitrated cycloalka[b]pyridines 5 could be successfully obtained and further used as useful intermediates for the synthesis of metacyclophanes, 4 pharmacophores, 8 and biologically active compounds. 9 Scheme 1.…”

mentioning

confidence: 99%

An Efficient Synthesis of Nitrated Cycloalka[b]pyridines

Asahara

Nishiwaki

2014

Synthesis

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

An Efficient Synthesis of Nitrated Cycloalka[b]pyridines

Asahara

Nishiwaki

2014

Synthesis

View full text Add to dashboard Cite

show abstract

Inhibitors of Gastric Acid Secretion

Roberts¹,

McDonald²

2003

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

The discovery of potent and selective inhibitors of gastric acid secretion now negates the need for surgical intervention in the treatment of many hypersecretory disorders. The side effects associated with cholinergic antagonists has led to their being superseded by the use of selective histamine H 2 ‐receptor antagonists (cimetidine, ranitidine, famotidine) and the more potent irreversible proton‐pump inhibitors (omeprazole, rabeprazole, lansoprazole, pantoprazole, esomeprazole). Current therapeutic regimes for the treatment of ulcer disease recommend concurrent proton‐pump administration while eradicating Helicobacter pylori , a bacterial infection that is strongly associated with ulcer formation. Because achlorhydria increases the likelihood of gastrointestinal infection, current research within this area is now targeting the design of reversible proton‐pump inhibitors and CCK 2 /gastrin‐receptor antagonists. These newer therapeutic approaches, however, are unlikely to produce the rapid and potent inhibition of acid secretion realized by the irreverisble PPIs, which in addition have few side effects and a proven track record of success. Key drug developments in the treatment of acid hypersecretion, from the anticholinergic agents to the highly potent and effective proton‐pump inhibitors currently in use, are covered in this chapter.

show abstract